Enterprise Value
189M
Cash
25.71M
Avg Qtr Burn
-7.966M
Short % of Float
7.71%
Insider Ownership
33.27%
Institutional Own.
13.71%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CAN-2409 Details Cancer, Solid tumor/s, Intermediate/high-risk Prostate cancer | Phase 3 Data readout | |
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic cancer, Cancer | Phase 2 Data readout | |
CAN-2409 Details Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer | Phase 2 Data readout | |
CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Update | |
CAN-3110 Details Solid tumor/s, Cancer, Glioma | Phase 1b Data readout | |
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s | Failed Discontinued |